Pancreatic cancer is the third most common cause of cancer-related deaths in the United
States. Although gemcitabine is the standard of care for most patients with pancreatic …

Simple Summary Pancreatic cancer is one of the most lethal cancers. Although complete
surgical resection is the only curative treatment for pancreatic cancer, a late diagnosis is …

Gemcitabine (GEM) resistance is one of the major causes of treatment failure in pancreatic
ductal adenocarcinoma (PDAC) in clinic. Here, through CRISPR/Cas9 activation library …

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal malignancies. Cancer
stem cells (CSCs), which are not targeted by current therapies, may be the reason for …

Abstract Nanoparticle albumin-bound (nab)-paclitaxel, an albumin-stabilized paclitaxel
formulation, demonstrates clinical activity when administered in combination with …

Abstract The Bcl-2 antagonist ABT-737 targets Bcl-2/Bcl-xL, but not Mcl-1, which may confer
resistance to this agent in various cancers with high levels of Mcl-1. Here, we showed that …

Background Pancreatic cancer retains a poor prognosis among the gastrointestinal cancers.
It affects 230,000 individuals worldwide, has a very high mortality rate, and remains one of …

Background: Resistance to gemcitabine is a major obstacle in the treatment of advanced
pancreatic cancer. Previous exploration of protein kinase inhibitors demonstrated that …

Pancreatic cancer (PC) remains one of the deadliest malignancies worldwide.
Chemoresistance is a significant clinical problem in pancreatic ductal adenocarcinoma …

Gemcitabine (GEM) alone and GEM‐based chemotherapy are the preferred regimens for
treating advanced unresectable and metastatic pancreatic cancer (PC). However, these …